Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
Sofia, Bulgaria, June 10, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 9, 2025 the Company sold 260 193 (two hundred sixty thousand one hundred ninety-three) repurchased own shares representing 0.14% of the share capital of the Company, at a total value of BGN 1 678 700.92 on the Bulgarian Stock Exchange, the average price per share was BGN 6.45.
Sofia, Bulgaria, June 9, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 6, 2025 the Company sold 3 310 (three thousand three hundred and ten) repurchased own shares representing 0.002% of the share capital of the Company, at a total value of BGN 21 581.80 on the Bulgarian Stock Exchange, the average price per share was BGN 6.52.
Sofia, Bulgaria, June 6, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 5, 2025 the Company sold 13 660 (thirteen thousand six hundred and sixty) repurchased own shares representing 0.008% of the share capital of the Company, at a total value of BGN 89 469.60 on the Bulgarian Stock Exchange, the average price per share was BGN 6.55.
Sofia, Bulgaria, June 5, 2025 – According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on June 4, 2025 the Company sold 42 210 (forty-two thousand two hundred and ten) repurchased own shares representing 0.02% of the share capital of the Company, at a total value of BGN 278 870,64 on the Bulgarian Stock Exchange, the average price per share was BGN 6,61.
